CA2975985A1 - Systeme therapeutique transdermique contenant de la valentonine et son utilisation comme medicament - Google Patents

Systeme therapeutique transdermique contenant de la valentonine et son utilisation comme medicament Download PDF

Info

Publication number
CA2975985A1
CA2975985A1 CA2975985A CA2975985A CA2975985A1 CA 2975985 A1 CA2975985 A1 CA 2975985A1 CA 2975985 A CA2975985 A CA 2975985A CA 2975985 A CA2975985 A CA 2975985A CA 2975985 A1 CA2975985 A1 CA 2975985A1
Authority
CA
Canada
Prior art keywords
vlt
during
melatonin
patch
plasma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2975985A
Other languages
English (en)
French (fr)
Inventor
Jean-Bernard Fourtillan
Marianne Fourtillan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Soeur Josefa Menendez
Original Assignee
Soeur Josefa Menendez
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Soeur Josefa Menendez filed Critical Soeur Josefa Menendez
Publication of CA2975985A1 publication Critical patent/CA2975985A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7092—Transdermal patches having multiple drug layers or reservoirs, e.g. for obtaining a specific release pattern, or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA2975985A 2015-02-04 2016-02-04 Systeme therapeutique transdermique contenant de la valentonine et son utilisation comme medicament Abandoned CA2975985A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15305161 2015-02-04
EP15305161.0 2015-02-04
PCT/EP2016/052376 WO2016124688A1 (fr) 2015-02-04 2016-02-04 Systeme therapeutique transdermique contenant de la valentonine et son utilisation comme medicament

Publications (1)

Publication Number Publication Date
CA2975985A1 true CA2975985A1 (fr) 2016-08-11

Family

ID=52573642

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2975985A Abandoned CA2975985A1 (fr) 2015-02-04 2016-02-04 Systeme therapeutique transdermique contenant de la valentonine et son utilisation comme medicament

Country Status (9)

Country Link
US (1) US10744122B2 (enExample)
EP (1) EP3253378B1 (enExample)
JP (1) JP6785779B2 (enExample)
KR (1) KR102361801B1 (enExample)
CN (1) CN107810003B (enExample)
CA (1) CA2975985A1 (enExample)
ES (1) ES2738633T3 (enExample)
HU (1) HUE045679T2 (enExample)
WO (1) WO2016124688A1 (enExample)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4134493A1 (de) * 1991-10-18 1993-04-22 Teves Gmbh Alfred Blockiergeschuetzte hydraulische bremsanlage
AU660336B2 (en) * 1991-10-18 1995-06-22 Alza Corporation Device for the transdermal administration of melatonin
FR2724384B1 (fr) 1994-09-14 1999-04-16 Cemaf Nouveaux derives de la 3,4-dihydro beta-carboline agonistes de la melatonine, leur procede de preparation et leur utilisation a titre de medicament
AU6595100A (en) * 1999-08-20 2001-03-19 Takeda Chemical Industries Ltd. Percutaneous absorption agents
IL155666A (en) * 2003-04-29 2013-12-31 Neurim Pharma 1991 Insomnia treatment
FR2898358B1 (fr) * 2006-03-08 2008-05-30 Macef Sa Association d'un antagoniste du recepteur 5ht2 et d'activateur du recepteur 5ht2 par modulation allosterique et leurs utilisations comme produits medicaux
FR2912405A1 (fr) * 2007-02-08 2008-08-15 Fourtillan Snc Derives des imidazo[1',5':1,6]pyrido[3,4-b]indoles et leur utilisation en therapeutique

Also Published As

Publication number Publication date
ES2738633T3 (es) 2020-01-24
JP2018507850A (ja) 2018-03-22
KR102361801B1 (ko) 2022-02-10
WO2016124688A1 (fr) 2016-08-11
EP3253378B1 (fr) 2019-05-08
US10744122B2 (en) 2020-08-18
HUE045679T2 (hu) 2020-01-28
CN107810003A (zh) 2018-03-16
EP3253378A1 (fr) 2017-12-13
JP6785779B2 (ja) 2020-11-18
CN107810003B (zh) 2022-05-03
KR20180004100A (ko) 2018-01-10
US20180000796A1 (en) 2018-01-04

Similar Documents

Publication Publication Date Title
Althaus et al. Preclinical characterization of zuranolone (SAGE-217), a selective neuroactive steroid GABAA receptor positive allosteric modulator
Mathé et al. Non‐NMDA excitatory amino acid receptors in the ventral tegmental area mediate systemic dizocilpine (MK‐801) induced hyperlocomotion and dopamine release in the nucleus accumbens
Rasiah et al. Windows into stress: a glimpse at emerging roles for CRHPVN neurons
Mathé et al. Differential actions of dizocilpine (MK-801) on the mesolimbic and mesocortical dopamine systems: role of neuronal activity
Enrico et al. The role of afferents to the ventral tegmental area in the handling stress-induced increase in the release of dopamine in the medial prefrontal cortex: a dual-probe microdialysis study in the rat brain
Takasu et al. Spinal hyperpolarization-activated cyclic nucleotide-gated cation channels at primary afferent terminals contribute to chronic pain
Calon et al. Alteration of glutamate receptors in the striatum of dyskinetic 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-treated monkeys following dopamine agonist treatment
Tao et al. Influence of inhibitory and excitatory inputs on serotonin efflux differs in the dorsal and median raphe nuclei
JP2009001588A (ja) パーキンソン病を治療するための方法並びに装置
Wang et al. Preparation of rotigotine-loaded microspheres and their combination use with L-DOPA to modify dyskinesias in 6-OHDA-lesioned rats
Schmid et al. Effects of somatostatin analogs on glucose homeostasis in rats
CA2682250A1 (fr) Complexes d'ibuprofene, de cyclodextrines et d'agents ternaires, et leurs utilisations en pharmaceutique
Sculptoreanu et al. Nitro-oleic acid inhibits firing and activates TRPV1-and TRPA1-mediated inward currents in dorsal root ganglion neurons from adult male rats
Pierrefiche et al. Biphasic effect of acamprosate on NMDA but not on GABAA receptors in spontaneous rhythmic activity from the isolated neonatal rat respiratory network
West et al. Intrastriatal infusion of (±)‐S‐nitroso‐N‐acetylpenicillamine releases vesicular dopamine via an ionotropic glutamate receptor‐mediated mechanism: an in vivo microdialysis study in chloral hydrate‐anesthetized rats
Timmerman et al. Electrical stimulation of the substantia nigra reticulata: detection of neuronal extracellular GABA in the ventromedial thalamus and its regulatory mechanism using microdialysis in awake rats
Dopico et al. Glycine release in the substantia nigra: interaction with glutamate and GABA
Crowder et al. Ethanol antagonizes kainate receptor-mediated inhibition of evoked GABAA inhibitory postsynaptic currents in the rat hippocampal CA1 region
EP3253378B1 (fr) Système thérapeutique transdermique contenant de la valentonine et son utilisation comme médicament
Dommett et al. Drug therapies for attentional disorders alter the signal-to-noise ratio in the superior colliculus
Jonkers et al. MK801 influences L-DOPA-induced dopamine release in intact and hemi-parkinson rats
Xiong et al. BEST1-mediated tonic excitation facilitates anxiety-like behaviors in a mouse model of chronic neuropathic pain
Prada et al. Melatonin decreases calcium levels in retinotectal axons of Xenopus laevis by indirect activation of group III metabotropic glutamate receptors
Beurrier et al. Role of glutamate transporters in corticostriatal synaptic transmission
Mayer et al. Microperfusion of 3-MPA into the brain augments GABA

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20210127

FZDE Discontinued

Effective date: 20240206